CXA 10

Drug Profile

CXA 10

Alternative Names: CXA-10

Latest Information Update: 16 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Complexa
  • Class Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Renal failure

Most Recent Events

  • 26 Jul 2017 Complexa plans a phase II trial for Focal segmental glomerulosclerosis in early 2018
  • 16 May 2016 Chemical information added
  • 12 Nov 2015 Complexa completes four phase I trials (NCT02127190, NCT02248051, NCT02460146, NCT02313064) in Acute kidney injury in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top